Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutant Advanced Non-small Cell Lung Cancer”

108 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 108 results

Early research (Phase 1)Ended earlyNCT03255083
What this trial is testing

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 13
Testing effectiveness (Phase 2)Looking for participantsNCT07742332
What this trial is testing

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Who this might be right for
EGFRNSCLC (Non-small Cell Lung Cancer)Locally Advanced Non-Small Cell Lung Cancer+2 more
Peng Zhang 160
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Testing effectiveness (Phase 2)Study completedNCT02879994
What this trial is testing

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Stage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center 11
Testing effectiveness (Phase 2)Ended earlyNCT04971187
What this trial is testing

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT01866410
What this trial is testing

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Looking for participantsNCT05394831
What this trial is testing

Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Who this might be right for
EGFR Mutant Advanced Non-small Cell Lung Cancer
J Ints Bio 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT03586453
What this trial is testing

Osimertinib In EGFR Mutant Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Dana-Farber Cancer Institute 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03392246
What this trial is testing

Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Dana-Farber Cancer Institute 25
Testing effectiveness (Phase 2)UnknownNCT03904823
What this trial is testing

Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 58
Large-scale testing (Phase 3)Not Yet RecruitingNCT07680790
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 850
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Not applicableUnknownNCT05377788
What this trial is testing

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaEGFR T790M
Samsung Medical Center 900
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Early research (Phase 1)Study completedNCT02503774
What this trial is testing

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Who this might be right for
Solid Tumors
MedImmune LLC 192
Early research (Phase 1)UnknownNCT05489731
What this trial is testing

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. 72
Not applicableStudy completedNCT06613633
What this trial is testing

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Who this might be right for
Third-generation TKINSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University 4,000
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Next Page